abacavir/lamivudine + darunavir/ritonavir — Competitive Intelligence Brief

abacavir/lamivudine + darunavir/ritonavir (abacavir/lamivudine + darunavir/ritonavir) competitive landscape: 6 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: NRTI + PI. Area: Infectious Diseases.

phase 3 NRTI + PI HIV-1 reverse transcriptase, HIV-1 protease Infectious Diseases Small molecule

Target snapshot

abacavir/lamivudine + darunavir/ritonavir (abacavir/lamivudine + darunavir/ritonavir) — University of Modena and Reggio Emilia. Abacavir/lamivudine is a combination of two nucleoside reverse transcriptase inhibitors (NRTIs) that work by inhibiting the replication of HIV-1, while darunavir/ritonavir is a protease inhibitor that blocks the protease enzyme, preventing the maturation of viral particles.

Comparator set (6 drugs)

Drug	Generic	Sponsor	Phase	Class	Target	Approval / PDUFA
abacavir/lamivudine + darunavir/ritonavir TARGET	abacavir/lamivudine + darunavir/ritonavir	University of Modena and Reggio Emilia	phase 3	NRTI + PI	HIV-1 reverse transcriptase, HIV-1 protease
emtricitabine, darunavir/cobicistat, maraviroc	emtricitabine, darunavir/cobicistat, maraviroc	Giovanni Di Perri	marketed	Antiretroviral combination (NRTI + PI + pharmacokinetic booster + CCR5 antagonist)	HIV reverse transcriptase, HIV protease, CYP3A4, CCR5 co-receptor
Tenofovir, emtricitabine, lopinavir/r	Tenofovir, emtricitabine, lopinavir/r	Hospital Clinic of Barcelona	marketed	Antiretroviral combination (NRTI + PI)	HIV reverse transcriptase, HIV protease
zidovudine+lamivudine+lopinavir/ritonavir	zidovudine+lamivudine+lopinavir/ritonavir	Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase and HIV protease
AZT+3TC+IDV+RTV	AZT+3TC+IDV+RTV	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + PI)	HIV reverse transcriptase; HIV protease
tenofovir + emtricitabine + atazanavir-ritonavir	tenofovir + emtricitabine + atazanavir-ritonavir	Juan A. Arnaiz	marketed	Antiretroviral combination (NRTI + PI/r)	HIV reverse transcriptase, HIV protease
tenofovir + abacavir + lopinavir/ritonavir	tenofovir + abacavir + lopinavir/ritonavir	Hospital Clinic of Barcelona	marketed	Antiretroviral combination therapy (NRTI + PI/boosted)	HIV reverse transcriptase, HIV protease

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (NRTI + PI class)

1. University of Modena and Reggio Emilia · 1 drug in this class